Groundbreaking Report on Medical Treatments
Improving the Odds for Cancer Patients
"As cancer rates soar worldwide the fight for a cure will boost the oncology market to well over $100 Billion by 2015."
As cancer rates soar worldwide the fight for a cure will boost the oncology market to well over $100 Billion by 2015.
Our national healthcare market is undergoing the most radical changes seen in our lifetimes. Group Purchasing Organization’s are keeping the margins tight, insurance companies and the FDA are slowing new treatments, it’s become critical for medical companies to influence the buying process as well as the buy-in process for new products and existing best in class treatments in order to remain profitable.
The expected breakthroughs in pharmacology, imaging, pain management, surgical and radiology treatments as well as new tools for administration and patient services, the competitive environment of Oncology has never been more difficult to navigate. Companies with long established relationships with physicians, clinics and hospitals are facing an ever growing cadre of HMO’s and GPO’s that are difficult to influence and hard to identify.
Companies are faced with slow paced clinical trials and difficulties with insurance approval. New discoveries and life saving treatments require credible education tools that key option influencers trust to help them break through the bureaucracy.
Oncology A.M.T. (Advanced Medical Treatment) will focus on the latest medical breakthroughs that optimize patient outcomes, control costs and help prevent administrative and technical errors. Working with the top industry experts, we will present a dynamic vision of the fight against cancer and the best practices necessary to keep a health care system running efficiently while remaining on the cutting edge.
The project will cover pharmaceuticals, medical devices, software, and services Oncology A.M.T. Upon completion it will be presented to the buyers responsible for the purchasing decisions at the top cancer treatment facilities named by the National Cancer Institute. The controlled circulation of 50,000 copies will include directors, procurement officers, Chief RN’s, Chief MD’s and C-level executives at these facilities as well as the GPO’s, HMO’s the FDA and Physicians involved in the buying process.
To reach and even greater audience and to allow open dialogue with key opinion influencers, Oncology A.M.T.’s online version will contain more related content as well as a subscription based digital-paper version of the report. The content will also be accessible by ipads and smart-phones. Our social media experts will use Facebook, Twitter and medical related forums to maintain a relationship with our readers.